Recombinant Antigens for Influenza Vaccine Strains

The name "influenza" is derived from the Latin word for "influence," and the pathogens that cause this disease are RNA viruses from the family Orthomyxoviridae. Influenza virus is divided into four main types (Influenza A, Influenza B, Influenza C, Influenza D), epidemics of seasonal influenza occur due to influenza A or B viruses. Influenza global pandemics occurred and killed tens of millions of people, with each of these pandemics being caused by the appearance of a new strain of the virus in humans, such as A/California/04/09 (H1N1) and A/Hong Kong/1/1968 (H3N2).

Annual vaccination is the primary and most effective way to prevent influenza and influenza-associated complications, especially for high-risk groups. Vaccination can reduce illness and lessen severity of infection. Flu viruses are constantly changing, so the vaccine composition is reviewed each year and updated as needed based on which influenza viruses are making people sick, the extent to which those viruses are spreading, and how well the previous season’s vaccine protects against those viruses. In recent decades, Vaccines against the flu are trivalent or quadrivalent, providing protection against an H1N1 strain, an H3N2 strain, and one or two IBV strains corresponding to the two IBV lineages (Yamagata and Victoria type).

Fig. 1. The development of influenza vaccine

Creative Diagnostics offers recombinant antigens for influenza vaccine strains. The product line covers Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins, from all WHO-recommended vaccine strains in 2015-2022. The reagents can be used to analyze immune responses against vaccine antigens. Welcome to contact us if you are in need of influenza vaccine antigens.

2021-2022

2020-2021

2019-2020

2018-2019

2017-2018

2016-2017

2015-2016

References:

1. Breen M, Nogales A, Baker SF, et al. Replication-Competent Influenza A Viruses Expressing Reporter Genes. Viruses. June 2016. 8(7):179.
2. Dan D, Rebecca R, Henrik Ö, et al. Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. Frontiers in Immunology. July 2018. 9: 1581.

Neutralizing Neuropilin-1 (NRP1) antibodies: Trusted Tools for SARS-CoV-2 Intervention Research

ELISA Kits for Peptide Drugs Detection

Nano Secondary Antibodies

Foodborne Pathogen Antibodies and Antigens

Tumor Marker Antigens - IVD Raw Materials

SARS-CoV-2 Antigens and Antibodies

Twitter Facebook